JP2024533263A - 神経原性疾患を処置するための方法 - Google Patents

神経原性疾患を処置するための方法 Download PDF

Info

Publication number
JP2024533263A
JP2024533263A JP2024514641A JP2024514641A JP2024533263A JP 2024533263 A JP2024533263 A JP 2024533263A JP 2024514641 A JP2024514641 A JP 2024514641A JP 2024514641 A JP2024514641 A JP 2024514641A JP 2024533263 A JP2024533263 A JP 2024533263A
Authority
JP
Japan
Prior art keywords
methyl
pyrrolo
pyrimidin
chloro
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024514641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533263A5 (https=
Inventor
スコット ジェイ バラザ
ジェフリー ケイ トリマー
ヨン ユ
シャオヤン チャン
Original Assignee
ピーティーシー セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピーティーシー セラピューティクス， インコーポレイテッド filed Critical ピーティーシー セラピューティクス， インコーポレイテッド
Publication of JP2024533263A publication Critical patent/JP2024533263A/ja
Publication of JP2024533263A5 publication Critical patent/JP2024533263A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2024514641A 2021-09-07 2022-09-06 神経原性疾患を処置するための方法 Pending JP2024533263A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163260942P 2021-09-07 2021-09-07
US63/260,942 2021-09-07
PCT/US2022/075966 WO2023039368A1 (en) 2021-09-07 2022-09-06 Methods for treating neurogenerative diseases

Publications (2)

Publication Number Publication Date
JP2024533263A true JP2024533263A (ja) 2024-09-12
JP2024533263A5 JP2024533263A5 (https=) 2025-09-17

Family

ID=85506882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024514641A Pending JP2024533263A (ja) 2021-09-07 2022-09-06 神経原性疾患を処置するための方法

Country Status (7)

Country Link
US (1) US20240382491A1 (https=)
EP (1) EP4398986A4 (https=)
JP (1) JP2024533263A (https=)
CN (1) CN118251225A (https=)
CA (1) CA3230996A1 (https=)
MX (1) MX2024002886A (https=)
WO (1) WO2023039368A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108519TA (en) 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012012656A2 (en) * 2010-07-21 2012-01-26 University Of South Florida Materials and methods for treating neurodegenerative diseases
EP2867236B1 (en) * 2012-06-29 2017-06-14 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
CA2973949C (en) * 2015-01-16 2023-07-11 The General Hospital Corporation Compounds for improving mrna splicing
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia

Also Published As

Publication number Publication date
EP4398986A1 (en) 2024-07-17
WO2023039368A1 (en) 2023-03-16
CA3230996A1 (en) 2023-03-16
CN118251225A (zh) 2024-06-25
MX2024002886A (es) 2024-05-24
US20240382491A1 (en) 2024-11-21
EP4398986A4 (en) 2025-07-09

Similar Documents

Publication Publication Date Title
EP4288441A1 (en) Methods for treating spinocerebellar ataxia type 3
US12398140B2 (en) Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia
US10787433B2 (en) Pyridazine derivatives as EAAT2 activators
US11377436B2 (en) EAAT2 enhancing molecules
US12286420B2 (en) EAAT2 activators and methods of using thereof
WO2022169868A1 (en) Compounds for treating spinocerebellar ataxia type 3
JP2024533263A (ja) 神経原性疾患を処置するための方法
US20210269442A1 (en) Fused ring derivative used as fgfr4 inhibitor
JP2024533264A (ja) 神経原性疾患を処置するための方法
JP2024533323A (ja) 神経変性疾患を処置するための方法
US20240051968A1 (en) Methods for treating spinocerebellar ataxia type 3
US20240041886A1 (en) Methods for treating spinocerebellar ataxia type 3
EP2626073A1 (en) Compound for use in the prevention and/or treatment of a neurogenerative disease or a disease involving an activation of phosphodiesterase-4 (PDE4)
US20250066356A1 (en) Lrrk2 inhibitors
HK40042691B (en) Eaat2 activators and methods of using thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250905